Nov 17, 2026
Eloralintide-Peptide.com Breaks Down Lilly's ObesityWeek 2026 EloraTZP Data and the First Participant-Reported Findings on Eloralintide. New analysis separates what changed at ObesityWeek from what did not: responder rates and exit-interview data are new, the headline weight-loss figures are not.
Los Angeles, United States, November 17, 2026 -- Los Angeles, CA – Eloralintide Peptide Research, an independent research resource covering the investigational amylin receptor agonist eloralintide, has published a plain-language breakdown of the data Eli Lilly presented at ObesityWeek 2026 in Washington, DC. The full analysis is available at https://eloralintide-peptide.com/eloralintide-obesityweek-2026/.
Lilly's presentations covered two sets of findings. The first was a group of new responder analyses from the 48-week Phase 2b trial of EloraTZP, the combination of eloralintide and tirzepatide, in 367 adults with obesity or overweight and type 2 diabetes (NCT06603571). The second was the first patient-experience data from the eloralintide Phase 2 monotherapy trial (NCT06230523).
What the new analyses reported
What did not change
The analysis stresses that ObesityWeek produced no new average weight-loss results. The headline figures still come from the September 30, 2026 readout at EASD: 23.3% mean weight loss with eloralintide 9 mg plus tirzepatide 15 mg, against 14.8% with tirzepatide 15 mg alone.
It also flags the limits of the new material. The exit-interview findings are qualitative and self-reported, not trial endpoints. Tolerability remains the open question: 10.8% to 27.0% of participants on the combinations stopped treatment because of side effects, compared with 2.9% on tirzepatide alone. Lilly's Phase 3 program uses a single-injection co-formulation with a slower escalation schedule, and whether that lowers discontinuations will not be known until those trials read out.
"Responder rates make strong headlines, but they are a different cut of the same September data, not a new result," said the editorial team at Eloralintide-Peptide.com. "Our job is to show readers which numbers are new, which are self-reported, and which questions only Phase 3 can answer."
Neither eloralintide nor EloraTZP is approved by the FDA or any other regulator. The site will continue to track the program, including updates analysts expect at Lilly's Innovation Day on December 7, 2026.
Read more articles on eloralintide research, trial data and sourcing, including a look at how the compound is being discussed on reddit.
About Eloralintide Peptide Research
Eloralintide Peptide Research is an independent research resource focused on a single compound. It covers published clinical trials, sourcing checks and certificates of analysis, with figures linked to their original sources. The site is not affiliated with Eli Lilly and Company.
Disclaimer: Content is for research and informational purposes only and is not medical advice. Eloralintide is an investigational compound that has not been approved by the FDA or any other regulator. Clinical trial results describe the investigational drug studied and are not evidence about any vendor's product.
Contact Info:
Name: Benson Jamison
Email: Send Email
Organization: Eloralintide Peptide Research
Phone: 3105613389
Website: https://eloralintide-peptide.com/
Release ID: 89209868
In case of encountering any inaccuracies, problems, or queries arising from the content shared in this press release that necessitate action, or if you require assistance with a press release takedown, we urge you to notify us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be readily available to promptly address your concerns within 8 hours, resolving any identified issues diligently or guiding you through the necessary steps for removal. The provision of accurate and dependable information is our primary focus.
High scorers automatically qualify for a senior citizen discount. View Entire Post ›
Now that Robert Pattinson has been revealed as the next James Bond, all eyes are on who will be cast as 007’s arch nemesis — and Brad Pitt is putting himself up for the job. At the premiere of his new film “The Further Mis-Adventures of Cliff Booth” on Monday night, the Oscar winner reacted […]
Emile Hirsch is to star in the Texas-set thriller “The Violet Crown,” which begins production in Mississippi and Texas in January. Aaron Harvey (“The Neighbor,” “Into The Ashes”) directs from an original screenplay penned by Mark Freiburger (“Between Borders”). Harvey’s latest film, “Come With Me,” starring Theo Rossi and Ron Perlman, premiered to solid reviews […]
Deadline has partnered with The Brit List to profile some of the emerging writers who have made this year’s ranking of the best unproduced UK film and TV projects. Launched in 2007, The Brit List has previously featured projects including The King’s Speech and Responsible Child. Here, we profile Polly Findlay, who has made the […]
‘Why Robert Pattinson?’: Actor’s road to landing 007 role comes to lightRobert Pattinson just took over the news cycle today, and despite being ‘too famous’ to play James Bond, the inside story of his road to 007 has just come out. The person responsible for dishing on everything is none...
Ali Fazal (“Mirzapur”), Tom Mison and Fiona Shaw are leading the cast of “A Passage to India,” Emmy-winning “Delhi Crime” filmmaker Richie Mehta’s five-part series version of E.M. Forster’s classic novel for the BBC and the Canadian Broadcasting Corporation. Mehta wrote the adaptation and is now directing it on location in India. Set in the […]
China’s Tencent Music Entertainment Group secured 30-day early release windows for selected major K-pop titles, including Blackpink star Jisoo’s latest single, after renewing its deal with Hybe, as the company posted third-quarter revenue of RMB8.94 billion ($1.33 billion), up 5.6% year on year. The growth came as podcast and audiobook platform Ximalaya, whose acquisition TME […]
The BBC and Canada’s CBC have confirmed their adaptation of E.M. Forster’s A Passage to India, casting Ali Fazal, Fiona Shaw and Tom Mison as leads. The beloved book just turned 100. Set against the backdrop of the British Raj and directed by Emmy-winner Richie Mehta (Delhi Crime), the series will chart Aziz’s optimistic attempts […]
There's a little something for every music fan in our guide to the 10 must-see concerts to attend from post-Thanksgiving through the beginning of 2027.
Catherine Townsend's new true-crime book, "How to Survive a Murder Investigation: A True Story of Death and Danger in the Ozarks," explores the limits — and costs — of investigating a cold murder case.
From the 1927 Rose Bowl to Peacock's Gold Zone, how NBC used baseball, the Olympics, the NBA and NFL to pioneer TV and streaming over 100 years.
Give a story this season: Authors Marla Frazee, Jon Klassen and Heidi Moreno share their favorite picture books they love to return to — and give as presents.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.